Surgical Management of Interdental Papilla Recession With Advanced Platelet Rich Fibrin or Connective Tissue Graft

August 31, 2021 updated by: Sanabel Osama Omran Barakat, Cairo University

Evaluation of Surgical Management of Interdental Papilla Recession With Advanced Platelet Rich Fibrin Compared to Subepthelial Connective Tissue Graft. A Randomized Controlled Trial

deficient interdental papillae witt be surgically reconstructed. in one group, connective tissue graft (SCTG) will be used for papillae augmentation, while in the other group, advanced platelet rich fibrin (A-PRF). the height of the papillae will be measured preoperatively as well as post operatively at 3, 6 ,9 and 12 months.

Study Overview

Status

Recruiting

Conditions

Detailed Description

The aim of this study is to compare the effect of A-PRF membrane to SCTG when used as grafting material with the Han and Takei's approach to reconstruct receding interdental papilla and assess deference in papilla height between the study groups.

The clinical parameters that will be evaluated are:

  • Papilla height (PH)
  • Clinical attachment level (CAL)
  • Probing depth (PD)
  • Post-operative patients' satisfaction about the esthetic outcome
  • Post-operative pain level among patients

Study settings:

This study will be conducted in the postgraduate periodontology clinics in the faculty of dentistry, Cairo University. The participants will be selected from the outpatient clinic of the department.

interventionsa:

The first visit:

  • Eligible participants will be interviewed to report medical and dental histories.
  • The participants will receive full mouth dental and periodontal examination.
  • Initial periodontal treatment (supragingival scaling and sub gingival debridement) as indicated.
  • Patients will be given oral hygiene instruction on proper tooth brushing and flossing.
  • They will be advised to use chlorhexidine mouth wash 0.12% twice daily for 2 weeks.

Second visit:

After 4-6 weeks of initial therapy, patients will be re-examined, and the baseline clinical parameters will be recorded as follows:

  • Full mouth plaque index and gingival index.
  • Site specific plaque index and gingival index.
  • Type of Papilla deficiency (classification).
  • Papilla height
  • Clinical attachment level
  • Probing depth

The patients then will be randomly allocated to one of the study groups.

Test group:

Deficient papillae in this group will be treated surgically and A-PRF membrane will be used as a grafting material.

Preparation of A-PRF:

A-PRF preparation protocol will be as described by (Clark et al. 2018):

A blood sample of 10 ml will be obtained from the patient and immediately centrifuged at 1300 rpm for 8 minutes.

Control group:

In this group, papilla recession will be treated surgically and the SCTG will be used as a grafting material.

sample size calculation was based on a previous study. fourteen experimental subjects and 14 control subjects are required to be able to reject the null hypothesis that the population means of the experimental and the control groups are equal with probability (power) 0.8. The type I error probability associated with this test of this null hypothesis is 0.05.

To compensate for anticipated missing data during follow up, this number is increased to 16 per group.

Recruitment

  • Patients will be selected from the outpatient clinic of the Oral Medicine and Periodontology Department, Faculty of Oral and Dental Medicine-Cairo University
  • Screening of patients will continue until the target sample is achieved.

Allocation

Randomization:

Patients will be randomly assigned to either test or control group using computer generated randomization (www.randomizer.org) which will be performed by the supervisor. The patients will be allocated to either test or control group.

Allocation concealment mechanism:

The two groups will be equally prepared for both surgical procedures. Then the decision of which group will receive papilla treatment with A-PRF (test) and which will receive papilla treatment with SCTG (control) will be taken according to the randomized numbers placed in opaque sealed envelopes. The number will be picked by the supervisor.

Implementation:

• All patients who provide an informed consent for participation as well as fulfill the inclusion criteria will be randomized.

Study Type

Interventional

Enrollment (Anticipated)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Cairo, Egypt
        • Recruiting
        • Faculty of Dentistry
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Be healthy adults older than 18 years of age and presenting at least one deficient papilla with papilla presence index 2 or 3
  • Have Interproximal CAL ≤ 3 mm
  • Have probing depth ≤ 3mm
  • Distance between the alveolar bone crest and contact point is less than 7mm.

Exclusion Criteria:

  • Smoking.
  • Pregnancy and lactation.
  • Carious and non-carious cervical lesion in the involved teeth around the papilla.
  • Restoration in teeth around the papilla (filling, crown, bridge, facings, clasp of a partial denture).
  • Open contacts and non-vital teeth
  • Poor oral hygiene with plaque index > 20 %.
  • Tooth mobility
  • History of medication in the previous 3 months
  • History of periodontal surgery in the site to be treated in the past 12 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: A-PRF
Surgical treatment A-PRF membrane
Surgical treatment of receding interdentalpapillae
Active Comparator: SCTG
Surgical treatment with SCTG
Surgical treatment of receding interdentalpapillae

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
papilla height
Time Frame: base line , 3, 6, 9, and 12 months
change of papillae height will be recorded using a graduated periodontal probe (UNC 15 probe)
base line , 3, 6, 9, and 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
patient satisfaction
Time Frame: 3 and 12 months
patients opinion about esthetic improvement
3 and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Hani ElNahass, Ph D, Cairo University
  • Principal Investigator: Samar ElKohouly, Ph D, Cairo University
  • Principal Investigator: sanabel barakat, MSC, Cairo University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2020

Primary Completion (Anticipated)

December 1, 2021

Study Completion (Anticipated)

December 1, 2022

Study Registration Dates

First Submitted

August 29, 2021

First Submitted That Met QC Criteria

August 31, 2021

First Posted (Actual)

September 1, 2021

Study Record Updates

Last Update Posted (Actual)

September 1, 2021

Last Update Submitted That Met QC Criteria

August 31, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • PER 331

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Recession

Clinical Trials on interdental papilla surgical reconstructiion

3
Subscribe